WOODCLIFF LAKE, N.J. Generic drug maker Par Pharmaceutical has launched a generic version of a drug used to treat gastroesophageal reflux disease, Par said Thursday.
Par launched omeprazole and sodium bicarbonate capsules in the 20 mg/1.1 g and 40 mg/1.1 g strengths. The drug is a generic version of Santarus’ Zegerid, which has annual sales of around $195 million, according to IMS Health. Because it was the first to win approval for a generic version of the drug, Par will have six months of market exclusivity in which to compete directly with Santarus’ product.
Also on Thursday, Cincinnati-based Prasco Labs launched an authorized generic version of Zegerid in the same strengths, under an agreement with Santarus. Authorized generics are branded drugs sold under their generic names at a discounted price, usually by a third-party company that has made an agreement with the branded drug manufacturer.